A growing number of Americans are trying popular weight-loss drugs touted by celebrities, health care providers and others.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...